These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34583518)

  • 41. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
    Zheng M; Huo J; Gu X; Wang Y; Wu C; Zhang Q; Wang W; Liu Y; Liu Y; Zhou X; Chen L; Zhou Y; Li H
    J Med Chem; 2021 Jun; 64(11):7839-7852. PubMed ID: 34038131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.
    Pinto DJ; Smallheer JM; Corte JR; Austin EJ; Wang C; Fang T; Smith LM; Rossi KA; Rendina AR; Bozarth JM; Zhang G; Wei A; Ramamurthy V; Sheriff S; Myers JE; Morin PE; Luettgen JM; Seiffert DA; Quan ML; Wexler RR
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1635-42. PubMed ID: 25728130
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
    Mackman RL; Steadman VA; Dean DK; Jansa P; Poullennec KG; Appleby T; Austin C; Blakemore CA; Cai R; Cannizzaro C; Chin G; Chiva JC; Dunbar NA; Fliri H; Highton AJ; Hui H; Ji M; Jin H; Karki K; Keats AJ; Lazarides L; Lee YJ; Liclican A; Mish M; Murray B; Pettit SB; Pyun P; Sangi M; Santos R; Sanvoisin J; Schmitz U; Schrier A; Siegel D; Sperandio D; Stepan G; Tian Y; Watt GM; Yang H; Schultz BE
    J Med Chem; 2018 Nov; 61(21):9473-9499. PubMed ID: 30074795
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitors for E3 ubiquitin ligases.
    Lydeard JR; Harper JW
    Nat Biotechnol; 2010 Jul; 28(7):682-4. PubMed ID: 20622837
    [No Abstract]   [Full Text] [Related]  

  • 45. Development and characterization of monomeric N-end rule inhibitors through in vitro model substrates.
    Sriram S; Lee JH; Mai BK; Jiang Y; Kim Y; Yoo YD; Banerjee R; Lee SH; Lee MJ
    J Med Chem; 2013 Mar; 56(6):2540-6. PubMed ID: 23432203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
    Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
    Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retinal penetration of calpain inhibitors in rats after oral administration.
    Shirasaki Y; Yamaguchi M; Miyashita H
    J Ocul Pharmacol Ther; 2006 Dec; 22(6):417-24. PubMed ID: 17238807
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay.
    Foley CA; Potjewyd F; Lamb KN; James LI; Frye SV
    ACS Chem Biol; 2020 Jan; 15(1):290-295. PubMed ID: 31846298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluating Ligands for Ubiquitin Ligases Using Affinity Beads.
    Dobrodziej J; Dong H; Zimmermann K; Hickey CM
    Methods Mol Biol; 2021; 2365():59-75. PubMed ID: 34432239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors.
    Pemberton N; Mogemark M; Arlbrandt S; Bold P; Cox RJ; Gardelli C; Holden NS; Karabelas K; Karlsson J; Lever S; Li X; Lindmark H; Norberg M; Perry MWD; Petersen J; Rodrigo Blomqvist S; Thomas M; Tyrchan C; Westin Eriksson A; Zlatoidsky P; Öster L
    J Med Chem; 2018 Jun; 61(12):5435-5441. PubMed ID: 29852070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of a new class of glucosylceramide synthase inhibitors.
    Koltun E; Richards S; Chan V; Nachtigall J; Du H; Noson K; Galan A; Aay N; Hanel A; Harrison A; Zhang J; Won KA; Tam D; Qian F; Wang T; Finn P; Ogilvie K; Rosen J; Mohan R; Larson C; Lamb P; Nuss J; Kearney P
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6773-7. PubMed ID: 21974949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced Oral Bioavailability of Domperidone with Piperine in Male Wistar Rats: Involvement of CYP3A1 and P-gp Inhibition.
    Athukuri BL; Neerati P
    J Pharm Pharm Sci; 2017; 20():28-37. PubMed ID: 28459658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.
    Blaquiere N; Villemure E; Staben ST
    J Med Chem; 2020 Aug; 63(15):7957-7985. PubMed ID: 32142281
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-Throughput Screening of HECT E3 Ubiquitin Ligases Using UbFluor.
    Foote PK; Krist DT; Statsyuk AV
    Curr Protoc Chem Biol; 2017 Sep; 9(3):174-195. PubMed ID: 28910856
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preparation and evaluation of self-microemulsifying drug delivery system of baicalein.
    Liu W; Tian R; Hu W; Jia Y; Jiang H; Zhang J; Zhang L
    Fitoterapia; 2012 Dec; 83(8):1532-9. PubMed ID: 22982454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PROTACs: A novel strategy for cancer therapy.
    Liu J; Ma J; Liu Y; Xia J; Li Y; Wang ZP; Wei W
    Semin Cancer Biol; 2020 Dec; 67(Pt 2):171-179. PubMed ID: 32058059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Overview of approaches for screening for ubiquitin ligase inhibitors.
    Sun Y
    Methods Enzymol; 2005; 399():654-63. PubMed ID: 16338387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Buchwald-Hartwig Protocol to Enable Rapid Linker Exploration of Cereblon E3-Ligase PROTACs*.
    Hayhow TG; Borrows REA; Diène CR; Fairley G; Fallan C; Fillery SM; Scott JS; Watson DW
    Chemistry; 2020 Dec; 26(70):16818-16823. PubMed ID: 32706492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.